Maia Biotech Q2 FY26 net loss widens 49% to $7.94 million

• Maia Biotechnology posted a net loss of $7.94 million in Q2 2026, widening 49% from a year earlier.
• Operating loss widened 61% to $8.32 million as R&D expense climbed 81% to $5.64 million, G&A rose 30% to $2.68 million.
• Interest income increased 197% to $236,320; other income turned positive to $373,664, supported by $207,173 in grant income.
• Net proceeds of about $33 million from March equity offerings are expected to fully fund the ongoing Phase 3 THIO-104 NSCLC trial.
• Phase 2 THIO-101 Part C showed a 90.5% disease control rate in 21 efficacy-evaluable 3L NSCLC patients as of July 6, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-036764), on August 10, 2026, and is solely responsible for the information contained therein.